Marine Bromophenol Derivatives as a Novel Class of Potent Small-Molecule STING Agonists.
Fuente:
PubMed
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Current issues in molecular biology
2026
|
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1868266092663668737 |
|---|---|
| author | Tang, Manqing Guo, Qiuhui Wang, Ping Li, Yunfei Jiang, Bo |
| author_facet | Tang, Manqing Guo, Qiuhui Wang, Ping Li, Yunfei Jiang, Bo Tang, Manqing Guo, Qiuhui Wang, Ping Li, Yunfei Jiang, Bo |
| collection | PubMed - marine biology |
| contents | Marine Bromophenol Derivatives as a Novel Class of Potent Small-Molecule STING Agonists. Tang, Manqing Guo, Qiuhui Wang, Ping Li, Yunfei Jiang, Bo Activation of the stimulator of interferon genes (STING) pathway has emerged as a promising strategy for cancer immunotherapy. However, the initial cyclic dinucleotide (CDN) analogs developed as STING agonists have shown limited efficacy in clinical trials, prompting interest in non-CDN small-molecule alternatives. In this study, we identified a novel series of bromophenol derivatives as effective STING agonists. Among these derivatives, OSBP63 robustly activated the STING signaling pathway, resulting in enhanced phosphorylation of interferon regulatory factor 3 (p-IRF3) and increased secretion of interferon-β (IFN-β). Co-administration of Marine Bromophenol Derivative (OSBP63) with paclitaxel (PTX), a conventional anticancer drug, significantly suppressed B-cell lymphoma-2 (BCL-2) expression and protein kinase B (AKT) phosphorylation, thereby demonstrating pronounced anti-tumor activity in a mouse model of breast cancer. These findings suggest that OSBP63 represents a promising non-CDN small-molecule STING agonist candidate, offering a valuable lead for future anticancer therapeutic development. |
| format | Artículo científico |
| id | pubmed_41614892 |
| institution | PubMed |
| language | en |
| publishDate | 2026 |
| publisher | Current issues in molecular biology |
| record_format | pubmed |
| spellingShingle | Marine Bromophenol Derivatives as a Novel Class of Potent Small-Molecule STING Agonists. Tang, Manqing Guo, Qiuhui Wang, Ping Li, Yunfei Jiang, Bo Marine Bromophenol Derivatives as a Novel Class of Potent Small-Molecule STING Agonists. Tang, Manqing Guo, Qiuhui Wang, Ping Li, Yunfei Jiang, Bo Activation of the stimulator of interferon genes (STING) pathway has emerged as a promising strategy for cancer immunotherapy. However, the initial cyclic dinucleotide (CDN) analogs developed as STING agonists have shown limited efficacy in clinical trials, prompting interest in non-CDN small-molecule alternatives. In this study, we identified a novel series of bromophenol derivatives as effective STING agonists. Among these derivatives, OSBP63 robustly activated the STING signaling pathway, resulting in enhanced phosphorylation of interferon regulatory factor 3 (p-IRF3) and increased secretion of interferon-β (IFN-β). Co-administration of Marine Bromophenol Derivative (OSBP63) with paclitaxel (PTX), a conventional anticancer drug, significantly suppressed B-cell lymphoma-2 (BCL-2) expression and protein kinase B (AKT) phosphorylation, thereby demonstrating pronounced anti-tumor activity in a mouse model of breast cancer. These findings suggest that OSBP63 represents a promising non-CDN small-molecule STING agonist candidate, offering a valuable lead for future anticancer therapeutic development. |
| title | Marine Bromophenol Derivatives as a Novel Class of Potent Small-Molecule STING Agonists. |
| url | https://pubmed.ncbi.nlm.nih.gov/41614892/ |